PET Imaging of Brain Amyloid Using [11C]MeS-IMPY

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

30 participants

Study Classification

INTERVENTIONAL

Study Start Date

2006-12-01

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Alzheimer's disease is associated with accumulation in the brain of a protein called amyloid. The purpose of this study is to test the ability of a research drug to measure amyloid in brain using positron emission tomography (PET) and a research drug called \[11C\]MeS-IMPY.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Positron Emission Tomography of Amyloid in Alzheimer's Disease

NCT00205621

Alzheimer's Disease

SUSPENDED PHASE1

Amyloid Imaging With 11C-PiB in Healthy Aging and Mild Cognitive Impairment

NCT04505735

Alzheimer Disease Healthy Aging

TERMINATED

Brain Imaging in Elderly People and Individuals With Alzheimer's Disease

NCT00001917

Alzheimer's Disease Healthy

COMPLETED

Safety and Efficacy of Positron Emission Tomography (PET) Imaging With MNI-558

NCT01217021

Alzheimer Disease

COMPLETED EARLY_PHASE1

PET Whole Body Biodistribution and Test Retest Bain Imaging Studies Using a Phosphodiesterase 4 Inhibitor (R)-[11C]Rolipram

NCT00250172

Dosimetry Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Alzheimer's disease (AD) is characterized pathologically by the presence of beta-amyloid plaques in brain. A substantial body of research indicates that the presence of increased beta -amyloid peptide is neurotoxic, and may initiate further pathology observed in AD including neurofibrillary tangles, synaptic loss and dysfunction, and neurodegeneration. There are multiple binding sites available on beta-amyloid plaques. Three clearly identified sites are Congo-red type, Thioflavin-T type, and FDDNP type. Radioligands currently under development using positron emission tomography (PET) for studying beta-amyloid in clinical research or drug development are based on Thioflavin-T site, such as \[11C\]PIB and \[11C\]SB-13. Though variously effective, these radioligands have one or more drawbacks with respect to measuring relative regional beta-amyloid densities. Therefore, we have recently developed \[11C\]MeS-IMPY as an alternative radioligand for imaging beta-amyloid, which will allow a more accurate quantification of amyloid plaques in AD brain. In the current protocol, we wish to evaluate \[11C\]MeS-IMPY in both healthy subjects and AD patients to determine the kinetics of brain imaging beta-amyloid plaques in AD patients.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Alzheimer's Disease Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Primary Study Purpose

TREATMENT

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

[11C]MeS-IMPY

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Healthy control subjects aged 18-90 years and AD patients aged 50-90, with history/physical exam, ECG, and laboratory tests.

Informed Consent.

AD Patients: Mini-Mental State Examination (score greater than or equal to 10).

AD Patients: Meet NINCDS-ADRDA criteria for probable AD.

Exclusion Criteria

1. Current or prior history of any alcohol or drug abuse.
2. Severe systemic disease based on history and physical exam.
3. Positive result on urine screen for illicit drugs.
4. Laboratory tests with clinically significant abnormalities.
5. Prior participation in other research protocols or clinical care in the last year such that radiation exposure would exceed the annual limits.
6. Pregnancy or breast feeding.
7. Claustrophobia.
8. Presence of ferromagnetic metal in the body or heart pacemaker.
9. History of brain disease other than Alzheimer's disease.
10. Unable to lay on one's back for the PET/MRI scan.

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes